Lerodalcibep Biosimilar Fusion Protein (PCSK9) for Research
Pre-Made Lerodalcibep Biosimilar, Fusion Protein targeting PCSK9 fused with ALB (albumin, human serum albumin, HSA): Recombinant therapeutic protein targeting FH3/FHCL3/HCHOLA3/LDLCQ1/NARC-1/NARC1/PC9 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Lerodalcibep is a recombinant fusion protein of a proprotein convertase subtilsin-kexin type 9 (PCSK9)-binding domain (adnectin) and human serum albumin (HAS). Binding of adnectin to PCSK9 prevents the interaction between PCSK9 and the LDL receptor. Linkage of HAS to the adnectin increases the half-life of 12 to 15 days. PCSK9 inhibitors are a new class of drugs that lower LDL, or “bad,” cholesterol. These agents target and inactivate proprotein convertase subtilsin-kexin type 9 (PCSK9), a hepatic protease that attaches and internalizes LDL receptors into lysosomes hence promoting their destruction.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-890-1mg | 1mg | 3090 |
| GMP-Bios-INN-890-10mg | 10mg | |
| GMP-Bios-INN-890-100mg | 100mg | |
| GMP-Bios-INN-890-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Lerodalcibep Biosimilar, Fusion Protein targeting PCSK9 fused with ALB (albumin, human serum albumin, HSA): Recombinant therapeutic protein targeting FH3/FHCL3/HCHOLA3/LDLCQ1/NARC-1/NARC1/PC9 |
| INN Name | Lerodalcibep |
| Target | PCSK9 |
| Format | Fusion Protein |
| Derivation | synthetic construct |
| Species Reactivity | human |
| CH1 Isotype | Fusion - Alternative to antigen receptors (domain scaffold: FN1 F10, fibronectin domain F10) |
| VD LC | Fusion - Alternative to antigen receptors (domain scaffold: FN1 F10, fibronectin domain F10) |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | LIB Therapeutics, LLC (Cincinnati OH USA) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | Alternative to antigen receptors, domain scaffold FN1 F10, fibronectin F10 (Adnectin™) |
About target - PCSK9
1. Protein Proprotein convertase subtilisin/kexin type 9
2. Gene PCSK9
3. Organism Homo sapiens (Human)
Function
Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments (PubMed:18039658).
Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation (PubMed:18799458, PubMed:17461796, PubMed:18197702, PubMed:22074827).
Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway (PubMed:18660751).
Inhibits epithelial Na+ channel (ENaC)-mediated Na+ absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways.
Cofactori
Ca2+
Activity regulationi
Its proteolytic activity is autoinhibited by the non-covalent binding of the propeptide to the catalytic domain. Inhibited by EGTA.

